Working... Menu

HydroCoil Cerebral Aneurysm Treatment Trial (HCAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01195129
Recruitment Status : Terminated (Due to results shown by the Cerecyte Clinical Trial, HCAT stopped enrolling.)
First Posted : September 3, 2010
Last Update Posted : December 12, 2014
Microvention-Terumo, Inc.
Information provided by (Responsible Party):
University of Virginia

Brief Summary:
The study will compare clinical and angiographic outcomes in patients receiving Hydrocoil aneurysm treatment versus patients receiving non-HydroCoil aneurysm treatment.

Condition or disease Intervention/treatment Phase
Intracerebral Aneursym Device: MicroVention Hydrogel coil Device: Non-hydrogel coils Phase 4

Detailed Description:
With prospective, randomized trials in progress evaluating the effectiveness of Hydrocoils and Cerecyte coils in comparison to bare platinum coils, the next step is a direct comparison of Hydrocoils and non-HydroCoils (Cerecyte or Platinum). Considering the increased costs to society of treatment with these new coils, it is essential that the benefits of the new technology are properly evaluated against the existing platinum coil technology in a scientifically valid manner.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 215 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: HydroCoil Cerebral Aneurysm Treatment Trial
Study Start Date : December 2008
Actual Primary Completion Date : April 2013
Estimated Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aneurysms

Arm Intervention/treatment
MicroVention Hydrogel Coils
FDA approved and in common use for cerebral aneurysm treatment.
Device: MicroVention Hydrogel coil
Micro Vention Hydrogel Coils

Active Comparator: Non-hydrogel coils
Cerecyte or bare platinum coils (FDA approved and in common use for treatment of cerebral aneurysm).
Device: Non-hydrogel coils
Cerecyte or bare platinum coils

Primary Outcome Measures :
  1. Occlusion rate [ Time Frame: 12 - 18 months ]
    Angiographic occlusion, improvement or no change in the post-coiling appearance of the aneurysm as judged by an independent core lab on follow-up angiography at 12-18 months after endovascular treatment.

Secondary Outcome Measures :
  1. Treatment related morbidity and mortality [ Time Frame: 12-18 months ]
    Treatment related morbidity and mortality, as measured by the NIH stroke scale;

  2. Packing density [ Time Frame: 12-18 months ]
    Packing density as measured by volumetric filling of the aneurysm.

  3. Clinical outcome [ Time Frame: 6 months ]
    Clinical outcome as measured by Modified Rankin Scale

  4. Clinical Outcome [ Time Frame: 12-18 months ]
    Clinical outcome as measured by the Modified Rankin scale

  5. Re-bleed rates [ Time Frame: 12-18 months ]
    Comparison of rebleed rates at 12-18 months

  6. Re-treatment rates [ Time Frame: 12-18 months ]
    Comparison of re-treatment rates at 12-18 months post treatment.

  7. Cost of treatment [ Time Frame: 12-18 months ]
    Comparison of cost of treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient presenting with a ruptured or un-ruptured cerebral aneurysm appropriate for endovascular treatment as determined by the neurovascular team (neurosurgeon/neurointerventionalist)
  2. The neurointerventionalist believes that the aneurysm can be safely treated with either Cerecyte or Hydrogel.
  3. Patients between (and including) 21 and 90 years of age.
  4. Patient HUNT AND HESS Grade 0-3.
  5. Patient has given fully informed consent to endovascular coiling procedure. If patient cannot consent for themselves, appropriate written consent has been sought from their next of kin, or from appropriate power of attorney.
  6. Aneurysm 5-20mm in maximum diameter.
  7. Patient is willing and able to return for clinical evaluation and follow-up imaging evaluation (angiography or MRA) at both 6-months and 12-18 months after endovascular treatment.
  8. The patient has not been previously randomized into this or another related ongoing trial.
  9. The aneurysm has not previously been treated (by coiling or clipping).

Exclusion Criteria:

  1. Patient has more than one aneurysm requiring treatment in the current treatment session If a patient has multiple aneurysms, but only one will be treated at the time of enrollment, they are eligible for the trial. (Additional aneurysms may be treated at a later date, and may be treated with any coil type that the operator chooses).
  2. Target aneurysm has had previous coil treatment or surgically clipped.
  3. Patient has an H&H score of 4 or 5 after subarachnoid hemorrhage (SAH).
  4. Inability to obtain informed consent.
  5. Medical or surgical co-morbidity such that the patient's life expectancy is less than 1 year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01195129

Layout table for location information
United States, California
Mercy Stroke Center
Carmichael, California, United States
University of Southern California
Los Angeles, California, United States
United States, Florida
University of Florida
Gainesville, Florida, United States
United States, Missouri
Saint Louis University
St. Louis, Missouri, United States
United States, New York
St. Luke's/Roosevelt Hospital Center
New York, New York, United States
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States
United States, South Carolina
Medical college of South Carolina
Charleston, South Carolina, United States
United States, Texas
University of Texas Southwest Medical Center
Dallas, Texas, United States
The Methodist Research Institute
Houston, Texas, United States
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sentara Norfolk General Hospital
Norfolk, Virginia, United States
Sponsors and Collaborators
University of Virginia
Microvention-Terumo, Inc.
Layout table for investigator information
Principal Investigator: Avery J Evans, MD University of Virginia

Layout table for additonal information
Responsible Party: University of Virginia Identifier: NCT01195129     History of Changes
Other Study ID Numbers: 13861
First Posted: September 3, 2010    Key Record Dates
Last Update Posted: December 12, 2014
Last Verified: December 2014

Keywords provided by University of Virginia:
cerebral aneursym

Additional relevant MeSH terms:
Layout table for MeSH terms
Intracranial Aneurysm
Vascular Diseases
Cardiovascular Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases